Cargando…

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted cancer therapies. However, little is known about the molecular determinants of cancer cell sensitivity to FASN inhibitors (FASNis), which is a major roadblock to their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroeder, Barbara, Vander Steen, Travis, Espinoza, Ingrid, Venkatapoorna, Chandra M. Kurapaty, Hu, Zeng, Silva, Fernando Martín, Regan, Kevin, Cuyàs, Elisabet, Meng, X. Wei, Verdura, Sara, Arbusà, Aina, Schneider, Paula A., Flatten, Karen S., Kemble, George, Montero, Joan, Kaufmann, Scott H., Menendez, Javier A., Lupu, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531299/ https://www.ncbi.nlm.nih.gov/pubmed/34675185 http://dx.doi.org/10.1038/s41419-021-04262-x

Ejemplares similares

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α(6)β(1) drives endocrine resistance in breast cancer cells
por: Espinoza, Ingrid, et al.
Publicado: (2022)

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells
por: Menendez, Javier A., et al.
Publicado: (2016)

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Identification of Acetylation Sites of Fatty Acid Synthase (FASN) by Mass Spectrometry and FASN Activity Assay
por: Miao, Ting, et al.
Publicado: (2023)

Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2
por: Tramonti, Angela, et al.
Publicado: (2021)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021)

Nutritional Niches of Cancer Therapy-Induced Senescent Cells
por: Llop-Hernández, Àngela, et al.
Publicado: (2022)

Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
por: Heuer, Timothy S., et al.
Publicado: (2016)

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
por: O’Farrell, Marie, et al.
Publicado: (2022)

Variation in the Fatty Acid Synthase Gene (FASN) and Its Association with Milk Traits in Gannan Yaks
por: Shi, Bingang, et al.
Publicado: (2019)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers
por: Cuyàs, Elisabet, et al.
Publicado: (2016)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer
por: Gonzalez-Guerrico, Anatilde M., et al.
Publicado: (2016)

The fasn-1(g14ts) allele is a Gly1830Arg missense mutation in C. elegans FASN-1
por: Bai, Xiaofei, et al.
Publicado: (2020)

Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis
por: Goswami, Sudeshna, et al.
Publicado: (2016)

Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
por: Menendez, J A, et al.
Publicado: (2017)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells
por: Khan, Arif, et al.
Publicado: (2020)

FASN activity is important for the initial stages of the induction of senescence
por: Fafián-Labora, Juan, et al.
Publicado: (2019)

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

MAPK/P53-mediated FASN expression in bone tumors
por: Jiang, Ye, et al.
Publicado: (2017)

Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma
por: Sun, Tianhao, et al.
Publicado: (2019)

FASN-dependent de novo lipogenesis is required for brain development
por: Gonzalez-Bohorquez, Daniel, et al.
Publicado: (2022)

A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer
por: Yang, Li, et al.
Publicado: (2016)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Diallyl Sulfide-Mediated Modulation of the Fatty Acid Synthase (FASN) Leads to Cancer Cell Death in BaP-Induced Lung Carcinogenesis in Swiss Mice
por: Khan, Arif, et al.
Publicado: (2020)

FASN expression, angiogenesis and lymphangiogenesis in central and peripheral giant cell lesions
por: FALCI, Saulo Gabriel Moreira, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9bq4q424icc4cipn6hqs2b4cco